Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Wee-1 Inhibitor AZD1775 Combined with Carboplatin in p53 Mutated Epithelial Ovarian Cancer
2010-019106-16Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adavosertib in epithelial ovarian cancer (EOC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 2 more, sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and tolerability of AZD1775 + carboplatin and Preliminary anti-tumor activity. Started Mar 2010; status: active.
02
Drugs
adavosertib
03
Conditions
epithelial ovarian cancer (EOC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2010-019106-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019106-16.